TY  - JOUR
AU  - Ulasov, Ilya V.
AU  - Borovjagin, Anton
AU  - Laevskaya, Anastasia
AU  - Kamynina, Margarita
AU  - Timashev, Peter
AU  - Cerchia, Laura
AU  - Rozhkova, Elena A.
PY  - 2023
TI  - The IL13α 2R paves the way for anti-glioma nanotherapy
JO  - Genes & Diseases
SN  - 2352-4820
SP  - 89
EP  - 100
VL  - 10
IS  - 1
AB  - Glioblastoma (GBM) is one of the most aggressive (grade Ⅳ) gliomas characterized by a high rate of recurrence, resistance to therapy and a grim survival prognosis. The long-awaited improvement in GBM patients' survival rates essentially depends on advances in the development of new therapeutic approaches. Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnosis and management of brain cancers. In the current review, we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches. Moreover, we will summarize the main evidence for the potential of the IL-13R alpha 2 receptor (IL13α2R) targeting in GBM early diagnosis and experimental therapy.
UR  - https://doi.org/10.1016/j.gendis.2021.08.006
DO  - 10.1016/j.gendis.2021.08.006